Candriam S.C.A. Dyne Therapeutics, Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
A detailed history of Candriam S.C.A. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 390,956 shares of DYN stock, worth $11.8 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
390,956
Previous 533,273
26.69%
Holding current value
$11.8 Million
Previous $18.8 Million
25.38%
% of portfolio
0.08%
Previous 0.12%
Shares
8 transactions
Others Institutions Holding DYN
# of Institutions
207Shares Held
102MCall Options Held
186KPut Options Held
232K-
Atlas Venture Life Science Advisors, LLC8.02MShares$243 Million35.54% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$224 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.86MShares$208 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY6.82MShares$207 Million3.9% of portfolio
-
Janus Henderson Group PLC London, X06.81MShares$207 Million0.13% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.57B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...